BRCA1 and cancer: Clinical underascertainment of individuals with pathogenic BRCA1/2 variants may be associated with the failure to apply testing guideline criteria and the failure of criteria-based strategies to identify all true positives.10,11 Such underascertainment has been documented even in women with existing cancer diagnoses12,13 and has prompted calls for DNA sequence–based population screening.14